Masatoshi Jinnin

Masatoshi Jinnin

Auto-generated profile, based on publicly available information

Masatoshi Jinnin

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
MJMasatoshi Jinnin
Masatoshi Jinnin
HIHironobu Ihn
Hironobu Ihn
YMYoshihiro Mimura
Yoshihiro Mimura
YAYoshihide Asano
Yoshihide Asano
KYKenichi Yamane
Kenichi Yamane
KTKunihiko Tamaki
Kunihiko Tamaki

18 October 2012 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
TMTakeo Maekawa
Takeo Maekawa
MJMasatoshi Jinnin
Masatoshi Jinnin
MOMamitaro Ohtsuki
Mamitaro Ohtsuki
HIHironobu Ihn
Hironobu Ihn

1 January 2015 in Drug Discoveries & Therapeutics
Verified
Journal Article
Closed access
IKIkko Kajihara
Ikko Kajihara
HKHisashi Kanemaru
Hisashi Kanemaru
TMTaiga Miyake
Taiga Miyake
JAJun Aoi
Jun Aoi
SMShinichi Masuguchi
Shinichi Masuguchi
HIHironobu Ihn
Hironobu Ihn
The prognosis of cutaneous angiosarcoma is very poor compared with that of other skin malignancies. The main reason for this is the limited regimens of chemotherapy available for angiosarcoma, because it is resistant to most common chemotherapeutic agents. Therefore, there is an urgent need to identify new treatment options. Recently, S-1 and docetaxel therapy was reported to be effective for advanced gastric cancer and metastatic extramammary Paget's disease. Therefore, we treated paclitaxel-resistant angiosarcoma patient with S-1/docetaxel chemotherapy. The progression-free survival was 5.0 months although grade 3 adverse events such as diarrhea and neutropenia developed. Our data need to be confirmed in a large number of patients, but S-1/docetaxel chemotherapy as an additional regimen seems to be an effective treatment option for paclitaxel-resistant angiosarcoma.

1 January 2016 in Drug Discoveries & Therapeutics
Verified
Journal Article
Closed access
PDF file
SYSaori Yamada
Saori Yamada
MJMasatoshi Jinnin
Masatoshi Jinnin
IKIkkou Kajihara
Ikkou Kajihara
TNTaiji Nakashima
Taiji Nakashima
JAJun Aoi
Jun Aoi
HIHironobu Ihn
Hironobu Ihn
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 January 2015 in BioScience Trends
Verified
Journal Article
Closed access
PDF file
KNKayo Nakamura
Kayo Nakamura
NNNoriko Nakatsuka
Noriko Nakatsuka
MJMasatoshi Jinnin
Masatoshi Jinnin
TMTakamitsu Makino
Takamitsu Makino
IKIkko Kajihara
Ikko Kajihara
HIHironobu Ihn
Hironobu Ihn
Fms-like tyrosine kinase 3 (Flt-3) is a cytokine receptor expressed on the surface of bone-marrow progenitor of hematopoietic cells. Flt-3 ligands are produced by peripheral blood mononuclear cells, and found in various human body fluids. Flt-3 signal is involved in the regulation of vessel formation as well as B cell differentiation, suggesting that Flt-3 signal contributes to the pathogenesis of vascular abnormalities and immune dysregulation in rheumatic diseases. The aim of the present study is to examine serum Flt-3 ligand levels in patients with various rheumatic diseases, and to evaluate the possibility that serum Flt-3 ligand levels can be a useful disease marker. Sera were obtained from 20 dermatomyositis (DM) patients, 36 systemic sclerosis (SSc) patients, 10 systemic lupus erythematosus (SLE) patients, 10 scleroderma spectrum disorder (SSD) patients, 4 mixed connective tissue disease (MCTD) patients, and 12 normal subjects. Flt-3 ligand levels were determined with ELISA. Serum Flt-3 ligand levels were significantly elevated in patients with DM, SSc, SSD and MCTD compared to those in normal subjects. DM patients with elevated Flt-3 ligand levels were accompanied with significantly increased CRP levels and increased frequency of heliotrope rash than those with normal levels. In addition, SSc patients with elevated Flt-3 ligand levels showed significantly reduced frequency of nailfold bleeding. Serum Flt-3 ligand levels can be a marker of cutaneous manifestation in DM and a marker of microangiopathy in SSc. Clarifying the role of Flt-3 ligand in rheumatic diseases may lead to further understanding of these diseases and new therapeutic approaches.

8 November 2012
Verified
Closed access
SSShuichi Shimada
Shuichi Shimada
MJMasatoshi Jinnin
Masatoshi Jinnin
AOAki Ogata
Aki Ogata
TMTakamitsu Makino
Takamitsu Makino
IKIkko Kajihara
Ikko Kajihara
HIHironobu Ihn
Hironobu Ihn